Lung Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 13

Employees

  • Latest Deal Type
  • M&A

Lung Therapeutics General Information

Description

Developer of novel peptide drugs intended to facilitate treatments for fibrosis and lung conditions. The company's drugs trigger both survival signals for alveolar epithelial cells and destruction signals for unwanted fibrotic cells, enabling medical practitioners to treat idiopathic pulmonary fibrosis and loculated pleural effusion among other life-threatening lung diseases.

Contact Information

Website
www.lungtx.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 3801 South Capital of Texas Highway
  • Suite 330
  • Austin, TX 78704
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 3801 South Capital of Texas Highway
  • Suite 330
  • Austin, TX 78704
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lung Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Merger/Acquisition 31-Oct-2023 Completed Clinical Trials - Phase 2
12. Later Stage VC 04-Apr-2022 Completed Clinical Trials - Phase 2
11. Grant 21-Aug-2020 Completed Clinical Trials - Phase 1
10. Debt - PPP 14-Apr-2020 Completed Clinical Trials - Phase 1
9. Later Stage VC (Series C) 31-Oct-2019 Completed Clinical Trials - Phase 1
8. Accelerator/Incubator 01-Jan-2018 Completed Clinical Trials - Phase 1
7. Early Stage VC (Series B) 01-Mar-2016 Completed Clinical Trials - Phase 1
6. Grant 27-Oct-2015 Completed Clinical Trials - Phase 1
5. Early Stage VC (Series A) 10-Sep-2014 $2.75M $2.75M Completed Clinical Trials - Phase 1
4. Accelerator/Incubator 12-Mar-2014 Completed Clinical Trials - Phase 1
To view Lung Therapeutics’s complete valuation and funding history, request access »

Lung Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A 10,888,283 $0.000100 $0.02 $0.27 $0.27 1x $0.27 12.06%
To view Lung Therapeutics’s complete cap table history, request access »

Lung Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel peptide drugs intended to facilitate treatments for fibrosis and lung conditions. The company's drugs
Drug Discovery
Austin, TX
13 As of 2024

Tucson, AZ
 

Brighton, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lung Therapeutics Competitors (15)

One of Lung Therapeutics’s 15 competitors is Aqualung Therapeutics, a Venture Capital-Backed company based in Tucson, AZ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aqualung Therapeutics Venture Capital-Backed Tucson, AZ
Enterprise Therapeutics Venture Capital-Backed Brighton, United Kingdom
Avalyn Pharma Formerly VC-backed Boston, MA
Verona Pharma Corporate Backed or Acquired London, United Kingdom
Corbus Pharmaceuticals Holdings Formerly VC-backed Norwood, MA
You’re viewing 5 of 15 competitors. Get the full list »

Lung Therapeutics Patents

Lung Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024015857-A2 Modified caveolin-1 peptide formulations and methods of manufacturing and use thereof Inactive 12-Jul-2022
WO-2024015857-A3 Modified caveolin-1 peptide formulations and methods of manufacturing and use thereof Inactive 12-Jul-2022
WO-2023070069-A1 Modified caveolin-1 peptides for the treatment of chronic kidney disease Inactive 22-Oct-2021
WO-2023283639-A1 Epithelial sodium channel (enac) inhibitor conjugates and methods for use thereof Inactive 08-Jul-2021
WO-2022266410-A1 Modified caveolin-1 peptides for the treatment of post-acute covid-19 Inactive 17-Jun-2021 A61K38/177
To view Lung Therapeutics’s complete patent history, request access »

Lung Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lung Therapeutics Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
ACC Bioscience Incubator Accelerator/Incubator
Austin Technology Incubator Accelerator/Incubator Minority
Bios Partners Venture Capital Minority
Angel (individual) Minority
DEFTA Partners Venture Capital Minority
You’re viewing 5 of 16 investors. Get the full list »

Lung Therapeutics FAQs

  • When was Lung Therapeutics founded?

    Lung Therapeutics was founded in 2013.

  • Where is Lung Therapeutics headquartered?

    Lung Therapeutics is headquartered in Austin, TX.

  • What is the size of Lung Therapeutics?

    Lung Therapeutics has 13 total employees.

  • What industry is Lung Therapeutics in?

    Lung Therapeutics’s primary industry is Drug Discovery.

  • Is Lung Therapeutics a private or public company?

    Lung Therapeutics is a Private company.

  • What is Lung Therapeutics’s current revenue?

    The current revenue for Lung Therapeutics is .

  • How much funding has Lung Therapeutics raised over time?

    Lung Therapeutics has raised $65.8M.

  • Who are Lung Therapeutics’s investors?

    ACC Bioscience Incubator, Austin Technology Incubator, Bios Partners, , and DEFTA Partners are 5 of 16 investors who have invested in Lung Therapeutics.

  • Who are Lung Therapeutics’s competitors?

    Aqualung Therapeutics, Enterprise Therapeutics, Avalyn Pharma, Verona Pharma, and Corbus Pharmaceuticals Holdings are some of the 15 competitors of Lung Therapeutics.

  • When was Lung Therapeutics acquired?

    Lung Therapeutics was acquired on 31-Oct-2023.

  • Who acquired Lung Therapeutics?

    Lung Therapeutics was acquired by Rein Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process